BioCentury | Feb 27, 2020
Product Development

Feb. 26 Quick Takes: Takeda acquires PvP for celiac therapy; plus Lilly, Esperion, Supernus, Moderna, Taiho-Arcus, Twist-Sophia

Takeda gains another celiac candidate via PvP takeout   After PvP Biologics Inc. finished a Phase I trial demonstrating proof of concept of its celiac disease therapy, Takeda Pharmaceutical Co. Ltd. (Tokyo:4502; NYSE:TAK) exercised its...
BC Extra | Jan 11, 2020
Financial News

Pact’s $75M series C gives Vida’s Kite alumni long-sought stab at personalized cell therapy

By leading Pact Pharma Inc.’s $75 million series C round, the ex-Kite partners at Vida Ventures finally have a chance to advance neoantigen-specific T cells for solid tumors, an area of keen interest they weren’t...
BC Extra | Jan 7, 2020
Company News

In deal with Taiho and Astex, Merck gains another K-Ras program

A deal giving Merck rights to an oncology program targeting K-Ras could help the pharma further extend its dominance in lung cancer beyond market-leading PD-1 inhibitor Keytruda -- a therapy that has already shown effects...
BC Extra | Dec 31, 2019
Politics & Policy

China’s expanded list of drugs for centralized procurement comes with new rules

Following the nationwide expansion of China’s pilot program for centralized procurement of generics and off-patent originator drugs, Beijing is adding a second group of 33 drugs and unveiling new rules that could increase the number...
BC Extra | Nov 20, 2019
Financial News

Werewolf debuts with $56M to develop tumor-activated biologics

Emerging from stealth with a $56 million series A round, Werewolf Therapeutics is aiming to increase the therapeutic window of cytokines and immuno-stimulatory antibodies by masking their activity until they reach the tumor microenvironment. MPM...
BC Innovations | Oct 11, 2019
Product Development

What’s next for neoantigens

With Phase I data trickling in for first-generation vaccines, neoantigen companies are now pursuing new modalities, including cell therapy, and developing tools to expand the target space. Over a dozen companies have launched programs to...
BC Extra | Aug 30, 2019
Financial News

Aug. 30 Financial Quick Takes: Remiges launches second fund with $30M from Taiho; ERADA gets grant for malaria diagnostic

Taiho to invest $30M in Remiges' second venture fund  Remiges Ventures has launched its second biopharma fund, which will invest in seed and early stage pharmaceuticals and medical devices worldwide. Taiho Pharmaceutical Co. Ltd. (Tokyo,...
BC Extra | Aug 9, 2019
Financial News

ORIC raises $55M to fund trials in drug-resistant cancers

With a $55 million series D round and recent hires from Ignyta and Genentech, ORIC believes it has the money and the team to advance multiple drug-resistant cancer therapies through clinical studies. ORIC Pharmaceuticals Inc....
BioCentury | Jul 26, 2019
Finance

Taiho turns to incubation

Taiho is taking its investments earlier in product development with the launch of its second venture arm, Taiho Innovations, which will incubate seed and preseed companies in Japan. "The mission of Taiho Innovations is incubation,"...
BC Innovations | Jul 25, 2019
Emerging Company Profile

Axial: targeting gut microbe metabolites for CNS disorders

Microbiome play Axial is using small molecules to treat the gut end of the gut-brain axis for Parkinson's disease and autism. Co-founder and CEO David Donabedian told BioCentury that Axial Biotherapeutics Inc. believes that the...
Items per page:
1 - 10 of 363
BioCentury | Feb 27, 2020
Product Development

Feb. 26 Quick Takes: Takeda acquires PvP for celiac therapy; plus Lilly, Esperion, Supernus, Moderna, Taiho-Arcus, Twist-Sophia

Takeda gains another celiac candidate via PvP takeout   After PvP Biologics Inc. finished a Phase I trial demonstrating proof of concept of its celiac disease therapy, Takeda Pharmaceutical Co. Ltd. (Tokyo:4502; NYSE:TAK) exercised its...
BC Extra | Jan 11, 2020
Financial News

Pact’s $75M series C gives Vida’s Kite alumni long-sought stab at personalized cell therapy

By leading Pact Pharma Inc.’s $75 million series C round, the ex-Kite partners at Vida Ventures finally have a chance to advance neoantigen-specific T cells for solid tumors, an area of keen interest they weren’t...
BC Extra | Jan 7, 2020
Company News

In deal with Taiho and Astex, Merck gains another K-Ras program

A deal giving Merck rights to an oncology program targeting K-Ras could help the pharma further extend its dominance in lung cancer beyond market-leading PD-1 inhibitor Keytruda -- a therapy that has already shown effects...
BC Extra | Dec 31, 2019
Politics & Policy

China’s expanded list of drugs for centralized procurement comes with new rules

Following the nationwide expansion of China’s pilot program for centralized procurement of generics and off-patent originator drugs, Beijing is adding a second group of 33 drugs and unveiling new rules that could increase the number...
BC Extra | Nov 20, 2019
Financial News

Werewolf debuts with $56M to develop tumor-activated biologics

Emerging from stealth with a $56 million series A round, Werewolf Therapeutics is aiming to increase the therapeutic window of cytokines and immuno-stimulatory antibodies by masking their activity until they reach the tumor microenvironment. MPM...
BC Innovations | Oct 11, 2019
Product Development

What’s next for neoantigens

With Phase I data trickling in for first-generation vaccines, neoantigen companies are now pursuing new modalities, including cell therapy, and developing tools to expand the target space. Over a dozen companies have launched programs to...
BC Extra | Aug 30, 2019
Financial News

Aug. 30 Financial Quick Takes: Remiges launches second fund with $30M from Taiho; ERADA gets grant for malaria diagnostic

Taiho to invest $30M in Remiges' second venture fund  Remiges Ventures has launched its second biopharma fund, which will invest in seed and early stage pharmaceuticals and medical devices worldwide. Taiho Pharmaceutical Co. Ltd. (Tokyo,...
BC Extra | Aug 9, 2019
Financial News

ORIC raises $55M to fund trials in drug-resistant cancers

With a $55 million series D round and recent hires from Ignyta and Genentech, ORIC believes it has the money and the team to advance multiple drug-resistant cancer therapies through clinical studies. ORIC Pharmaceuticals Inc....
BioCentury | Jul 26, 2019
Finance

Taiho turns to incubation

Taiho is taking its investments earlier in product development with the launch of its second venture arm, Taiho Innovations, which will incubate seed and preseed companies in Japan. "The mission of Taiho Innovations is incubation,"...
BC Innovations | Jul 25, 2019
Emerging Company Profile

Axial: targeting gut microbe metabolites for CNS disorders

Microbiome play Axial is using small molecules to treat the gut end of the gut-brain axis for Parkinson's disease and autism. Co-founder and CEO David Donabedian told BioCentury that Axial Biotherapeutics Inc. believes that the...
Items per page:
1 - 10 of 363